No Set Deadline for Yervoy Price Reductions
Yervoy (ipilimumab), Bristol Myers Squibb's immunotherapy for melanoma and other cancers, has no fixed deadline or mandated timeline for price reductions. Pricing remains at Bristol Myers Squibb's discretion, driven by market dynamics, competition, and negotiations rather than regulatory deadlines.[1]
Why No Mandated Price Cuts?
U.S. drug pricing lacks government-imposed deadlines for reductions on branded drugs like Yervoy. Medicare negotiations under the Inflation Reduction Act targeted it for price talks starting in 2026, with potential cuts effective 2027, but this is negotiation-based, not a hard deadline.[2] European pricing pressures from health technology assessments can lead to voluntary cuts, but again, no fixed dates apply globally.
When Could Prices Drop?
- Patent Expiry: Yervoy's core composition patent (US 7,109,042) expires December 25, 2025 in the U.S., opening doors to generics or biosimilars that could force competition-driven cuts—potentially as early as 2026 if approvals follow.[3] Check DrugPatentWatch.com for full expiry details and challenges.
- Biosimilar Entry: No Yervoy biosimilars are FDA-approved yet; first filings could align post-2025, similar to Opdivo biosimilars expected around 2028.[3]
- Recent Trends: Bristol Myers Squibb cut Yervoy's U.S. list price by 10-15% in some packages in 2023 amid payer pushback, but without ongoing commitments.[1]
What Influences Future Reductions?
Payer negotiations, like those with CVS Caremark or Express Scripts, often yield rebates or tier changes without public deadlines. Inflationary pressures or new competitors (e.g., Amgen's tarlatamab) could accelerate drops. In contrast, countries like Australia saw Yervoy delisted from reimbursement in 2022 over cost, prompting localized pricing adjustments.[4]
Patient Access Options Now
Net prices for eligible patients average $150,000-$170,000 per course via copay assistance; programs like Bristol Myers' OneONCology cover out-of-pocket up to $25,000 annually.[1] Track updates via FDA Orange Book or DrugPatentWatch.com.
Sources
[1]: Bristol Myers Squibb financial reports (2023)
[2]: CMS Inflation Reduction Act tracker
[3]: DrugPatentWatch.com - Yervoy Patents
[4]: PBS Australia decisions